Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07220460 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder
A Phase 2 study of Bipolar I or II Disorder, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT07220460 is a Phase 2 study of Bipolar I or II Disorder that is actively recruiting participants, run by AbbVie. The registered enrollment target is 200 participants. The trial reports 20 study locations across 4 states.
The verdict
NCT07220460, a Phase 2 study of Bipolar I or II Disorder, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. The purpose of this study is to assess how safe and effective ABBV-932 is in treating participants with depressive episodes associated with bipolar I or II disorder. ABBV-932 is an investigational drug being developed for the treatment of depressive episodes in adult participants with bipolar I or II disorder. Participants with bipolar I or II disorder who are currently experiencing a depressive episode will enter the study and be treated with open-label ABBV-932. Approximately 200 adult participants with bipolar I or II disorder will be enrolled in approximately 50 sites in the United States and Puerto Rico. Participants will receive oral capsules of ABBV-932 for a 26-week treatment period. The treatment period will be followed by a safety follow-up (SFU) period of 30 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regularly scheduled visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions Studied
Interventions
- DRUG ABBV-932
Study Locations (20)
California
- Advanced Research Center /ID# 273474 - Anaheim
- Axiom Research /ID# 273482 - Colton
- Collaborative Neuroscience Research - Garden Grove /ID# 273492 - Garden Grove
- Sun Valley Research Center /ID# 273472 - Imperial
- Synergy San Diego /ID# 278340 - Lemon Grove
- Alliance for Research Alliance for Wellness /ID# 273477 - Long Beach
- Nrc Research Institute - Los Angeles /ID# 278450 - Los Angeles
- Excell Research /ID# 273483 - Oceanside
- Inland Psychiatric Medical Group Inc. /ID# 273471 - Temecula
- Sunwise Clinical Research /ID# 278165 - Walnut Creek
Florida
- Cns Healthcare - Jacksonville /ID# 278332 - Jacksonville
- GMI Florida - Central Miami Medical Institute /ID# 273486 - Miami
- Allied Biomedical Res Inst Inc /ID# 273476 - Miami
- Floridian Clinical Research - Miami Lakes /ID# 279379 - Miami Lakes
- K2 Medical Research - Orlando - South Orlando Avenue /ID# 273487 - Orlando
- Apg Research /ID# 278439 - Orlando
- Segal Trials - West Broward Outpatient Research Site /ID# 273496 - Tamarac
- Health Synergy Clinical Research /ID# 279384 - West Palm Beach
Arizona
- Ima Clinical Research Phoenix (Alea) /ID# 278047 - Phoenix
Connecticut
- Connecticut Clinical Research - Cromwell /ID# 278116 - Cromwell
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-09-30 |
| Est. Completion | 2027-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07220460
The ClinicalTrials.gov registry entry for NCT07220460 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bipolar I or II Disorder appearing as the primary indexed condition, and to 1 intervention - of which ABBV-932 is the first listed.
NCT07220460 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT07220460 about?
NCT07220460 is a clinical study titled "Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder". Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. The purpose of this study is to assess how safe and effective ABBV-932 is in treating participants with depressive episodes associated with bipolar I or II disorder. ABBV-932 is an...
What is the current status of trial NCT07220460?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-09-30. Estimated completion is 2027-04.
What conditions does trial NCT07220460 study?
This clinical trial studies the following conditions: Bipolar I or II Disorder.
What interventions are being tested in trial NCT07220460?
The interventions under investigation include: ABBV-932 (DRUG).
Who is sponsoring clinical trial NCT07220460?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07220460 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.